ALNOV:EPA
Novacyt SA
€0.46
arrow_downward
-0.32%(-0.0015) 1D
Oct 20, 5:35:20 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.47
High
€0.47
Low
€0.46
Mkt. cap
33.59M
Avg. vol.
235.63K
Volume
100.54K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
Open
€0.47
High
€0.47
Low
€0.46
Mkt. cap
33.59M
Avg. vol.
235.63K
Volume
100.54K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.37
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
ChartMill
·
1 hour ago
Most Active S&P 500 Stocks in Today's Session
FXEmpire
·
33 minutes ago
Dow Jones Price Forecast: Bulls Eye 57,000 as October 6 Low Remains Key
Insider Monkey
·
2 hours ago
Ciena (CIEN): Is the AI-Optical Boom Enough to Carry It Into the S&P 500?
Yahoo Finance
·
2 hours ago
United Therapeutics (UTHR): Can the Profit-Machine Biotech Finally Crack the S&P 500?
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and VĂ©lizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA